Philippe Rey Selected Research

Stem Cell Transplantation

1/2022

Rituximab in combination with adapted-dose of ifosfamide and etoposide as salvage treatment in elderly refractory/relapsed diffuse large B-cell lymphoma patients non-candidate for high dose therapy: a retrospective study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Philippe Rey Research Topics

Disease

1	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2022
1	Neoplasms (Cancer) 01/2021
1	Venous Thromboembolism 01/2019
1	Hemorrhage 01/2019
1	Thrombocytopenia (Thrombopenia) 01/2019
1	Thromboembolism 01/2019
1	Lymphadenopathy 10/2017
1	Lymphoma (Lymphomas) 01/2017
1	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 03/2015
1	Ulcerative Colitis 12/2013
1	Infected Aneurysm 12/2013
1	Salmonella Infections (Salmonellosis) 12/2013
1	Fibrosis (Cirrhosis) 11/2003
1	Familial duodenal atresia 11/2003
1	Pancreatitis 11/2003

Drug/Important Bio-Agent (IBA)

2	Rituximab (Mabthera)FDA Link 01/2022 - 03/2015
1	Ifosfamide FDA LinkGeneric 01/2022
1	Etoposide (VP 16)FDA LinkGeneric 01/2022
1	Lenalidomide (CC 5013)FDA Link 01/2019
1	Immunomodulating AgentsIBA 01/2019
1	Thalidomide (Thalomid)FDA Link 01/2019
1	apixabanIBA 01/2019
1	Hemoglobins (Hemoglobin)IBA 10/2017
1	Infliximab (Remicade)FDA Link 12/2013
1	CollagenIBA 11/2003

Therapy/Procedure

2	Therapeutics 01/2022 - 01/2017
1	Salvage Therapy 01/2022
1	Stem Cell Transplantation 01/2022
1	Drug Therapy (Chemotherapy) 01/2021
1	Conservative Treatment 11/2003